drugset / Trial / NCT05003986
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
Timeline
- Start
- 2021-08-12
- Primary completion
- 2027-03-12
- Completion
- 2027-04-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sparsentan | Small molecule | 400 mg | Oral |
| Subject | Sparsentan | Small molecule | 800 mg | Oral |